Warum arbeiten beim TRIPEL-NEG Mammakarzinom eine immunsup-pressive Chemotherapie und ein Immunmodulator-Antikörper zusammen?

Cortes J et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised placebo-controlled double-blind phase 3 clinical trial. Lancet 2020; 396: 1817.

Zusammenfassung: first-line treatment of metastatic triple-negative breast cancer with pembrolizumab–chemotherapy showed a significant and clinically meaningful improvement in progression-free survival versus placebo.

Präoperative Chemotherapie beim Pankreaskarzinom: klare und unklare Daten

Kunzmann V et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicenter randomised phase 2 trial. Lancet Gastroenterol Hepatol 2020; doi.org/10.1016/ S2468-1253(20)30330-7

Zusammenfassung: Nab-paclitaxel plus gemcitabine is similarly active and safe as nab-paclitaxel plus gemcitabine followed by FOLFIRINOX as induction chemotherapy for locally advanced pancreatic cancer. Although conversion to resectability was achieved in about a third of patients, additional evidence is required to determine whether this translates into improved overall survival.

Was lehrt uns die Coronavirus-Pandemie in der Onkologie?

Pennell NA et mult al. American Society of Clinical Oncology road to recovery report: learn-ing from the Covid-19 experience to improve clinical research and cancer care. J Clin Oncol 2020; doi.org/10.1200/JCO.20.02953

Zusammenfassung: This report provides a road map of actions that Congress, the Administration, ASCO, research sponsors, health systems, and other stakeholders in the healthcare system can take to help improve access to affordable and equitable care and clinical research, streamline excessive and unnecessary regulatory requirements in practice and research, and achieve improved outcomes for patients with cancer.

«Unhappy birthday to you! …»

Kato H, et al. Patient mortality after surgery on the surgeon’s birthday: observational study. Brit Med J 2020; 371: m4381

Zusammenfassung: Patients who received surgery on the surgeon’s birthday, experienced higher mortality compared with patients who underwent surgery on other days.